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CLINICAL GUIDELINES

American Society of Hematology living guidelines on the use of
anticoagulation for thromboprophylaxis in patients with COVID-19: July
2021 update on postdischarge thromboprophylaxis
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Background: COVID-19–related acute illness is associated with an increased risk of venous
thromboembolism (VTE).
Objective: These evidence-based guidelines of the American Society of Hematology (ASH) are intended
to support patients, clinicians, and other health care professionals in decisions about the use of anticoagulation for thromboprophylaxis in patients with COVID-19 who do not have conﬁrmed or suspected VTE.
Methods: ASH formed a multidisciplinary guideline panel, including 3 patient representatives, and
applied strategies to minimize potential bias from conﬂicts of interest. The McMaster University
GRADE Centre supported the guideline development process, including performing systematic
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evidence reviews (up to March 2021). The panel prioritized clinical questions and outcomes
according to their importance for clinicians and patients. The panel used the grading of
recommendations assessment, development, and evaluation (GRADE) approach to assess evidence
and make recommendations, which were subject to public comment.
Results: The panel agreed on 1 additional recommendation. The panel issued a conditional
recommendation against the use of outpatient anticoagulant prophylaxis in patients with COVID-19
who are discharged from the hospital and who do not have suspected or conﬁrmed VTE or another
indication for anticoagulation.

Summary of recommendations
Recommendation 3
The ASH guideline panel suggests that outpatient anticoagulant
thromboprophylaxis not be used for patients with COVID-19 who
are being discharged from the hospital and do not have suspected
or conﬁrmed venous thromboembolism (VTE) or another indication
for anticoagulation (conditional recommendation based on very low
).
certainty in the evidence about effects 丣

Remarks:




An individualized assessment of the patient’s risk of thrombosis
and bleeding and shared decision making are important when
deciding on whether to use postdischarge thromboprophylaxis.
Prospectively validated risk assessment models to estimate
thrombotic and bleeding risk in COVID-19 patients after hospital
discharge are not available.
The panel acknowledged that postdischarge thromboprophylaxis
may be reasonable for patients judged to be at high risk of thrombosis and low risk of bleeding.

Background
Hospitalization for acute medical illness is a common risk factor for
venous thromboembolism (VTE), with most such events occurring
after hospital discharge.1,2 Meanwhile, there is a high incidence of
thrombotic complications in patients hospitalized for COVID19–related acute illness or critical illness.3,4 However, there are limited reports regarding rates of VTE after discharge for patients who
have been hospitalized for COVID-19.5,6 Thus, there has been
much interest in establishing whether postdischarge pharmacological thromboprophylaxis in this population is warranted.

These guidelines are based on systematic reviews of evidence conducted under the direction of the McMaster University GRADE
(grading of recommendations, assessment, development and evaluations) Centre with international collaborators. This is an update of
the previous American Society of Hematology (ASH) guideline published in February 20217 and focuses on the role of thromboprophylaxis for patients discharged from the hospital after COVID-19. The
panel followed best practice for guideline development recommended by the Institute of Medicine and the Guidelines International
Network (GIN).8-10 The panel used the GRADE approach11-17 to
assess the certainty of the evidence and formulate recommendations. The recommendation is listed in Table 1.

Values and preferences




The guideline panel identiﬁed all-cause mortality, pulmonary
embolism (PE), deep vein thrombosis (DVT), and major bleeding
as critical outcomes and placed a high value on avoiding these
outcomes with the interventions assessed.
Panel members noted that there was possible uncertainty and variability in the relative value that patients place on avoiding major
bleeding events compared with reducing thrombotic events.

Explanations and other considerations
Please refer to the original ASH guidelines on the use of thromboprophylaxis for patients with COVID-19.7

Interpretation of strong and conditional
recommendations
Please refer to the original ASH guidelines on the use of thromboprophylaxis for patients with COVID-19.7

Introduction
Aims of these guidelines and specific objectives

Description of the health problem

Please refer to the original ASH guidelines on the use of thromboprophylaxis for patients with COVID-19.7 All recommendations and
updates to these living guidelines are accessible on the ASH
COVID-19 anticoagulation Web page.18

The COVID-19 pandemic has had a signiﬁcant public health impact.
As of 21 September 2021, over 229 million cases and 4.5 million
deaths have been attributed to COVID-19–related illness globally.19
It is estimated that 5% to 20% of infected patients require hospital
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Conclusions: This recommendation was based on very low certainty in the evidence, underscoring
the need for high-quality randomized controlled trials assessing the role of postdischarge thromboprophylaxis. Other key research priorities include better evidence on assessing risk of thrombosis
and bleeding outcomes in patients with COVID-19 after hospital discharge.

admission, of whom 5% to 15% may develop critical illness requiring intensive care support.20-22

In non–COVID-19 medical inpatients, most hospitalization-related
thrombotic events occur after discharge; heightened VTE risk may
extend until at least 1 month after discharge.1,27 Several risk assessment models (RAMs) in patients without COVID-19 have been
developed to assess the risk of VTE after hospitalization.24,28,29
However, randomized trials of postdischarge prophylaxis in patients
without COVID-19 have not shown a substantial absolute beneﬁt in
VTE reduction, and the 2018 ASH guidelines recommended
against postdischarge prophylaxis in medically ill patients who did
not have COVID-19, owing to a low absolute beneﬁt offset by an
increase in bleeding risk.26,30-32

We followed the same methods as published in the initial guideline,7
with the following important updates and differences for the recommendation reported herein:






Organization, panel composition, planning, and coordination:
with 1 exception, we retained the same panel members; no conﬂicts of interest emerged that would require exclusion of panel
members.
Guideline funding and management of conﬂicts of interest: Supplement 4 provides updated Participant Information Forms for all
panel members, detailing ﬁnancial and nonﬁnancial interests, as
well as the ASH conﬂict of interest policies agreed to by each
individual. Supplement 5 provides the updated complete Participant Information Forms of researchers on the systematic review
team who contributed to these guidelines.
Formulating speciﬁc clinical questions and determining outcomes of interest: this update of the guidelines focuses on 1
question: for patients with COVID-19 who are being discharged
from the hospital and who do not have suspected or conﬁrmed
VTE or another indication for anticoagulation, should we use
prophylactic-intensity direct oral anticoagulants, low-molecularweight heparin, unfractionated heparin, or fondaparinux vs no
anticoagulation?
We originally intended to include antiplatelet agents in the question, but we ultimately chose not to because of the lack of published evidence in COVID-19 patients. However, antiplatelet
agents may be included in living updates.

There is a belief that patients with COVID-19 may have a higher risk of
VTE after discharge than patients without COVID-19. However, available COVID-19–speciﬁc estimates do not bear this out. Although
there remains considerable uncertainty, published estimates of
postdischarge VTE in COVID-19 patients generally range from 0.5%
to 1.5%,5,6,33 comparable to the baseline risk of postdischarge VTE in
the non-COVID-19 population. Several clinical risk factors have been
found to be independently associated with postdischarge VTE after
COVID-19, including advanced age, cardiovascular disease, chronic
kidney disease, and intensive care unit (ICU) admission.5 However,
there are no RAMs that have been speciﬁcally derived and prospectively validated in patients with COVID-19 thus far, although nonCOVID RAMs have been externally validated in hospitalized patients
with COVID-19, and the COVID-thromboembolism score was derived
speciﬁcally from patients with COVID-19 with concomitant malignancy.34-36 Moreover, although the recent CORE-19 registry demonstrated a reduction in the composite outcome of VTE, arterial
thromboembolism (ATE), and all-cause mortality with postdischarge
anticoagulation, there remains a paucity of high-quality prospective
and randomized data. As such, the relative risks and beneﬁts of
postdischarge thromboprophylaxis remain uncertain in this population.
In this living guideline update, the role of postdischarge thromboprophylaxis after hospitalization for COVID-19 is addressed.

An evidence-to-decision framework was created for recommendation 3 (see “Recommendations”), by using the same methods as
the initial guideline.6 The systematic review to identify comparative
anticoagulation studies for the entire guideline was updated until 5
March 2021. The initial guideline’s literature search strategy (Supplement 6) was modiﬁed to add search terms for antiplatelet agents
for this guideline question. The protocol (Supplement 9) was modiﬁed to focus on inclusion of only randomized controlled trials for
other previously published recommendations. Baseline risk estimates for outcomes of patients with COVID-19 who were discharged from the hospital were based on studies identiﬁed using
the same overall systematic review as reported in the initial guideline, updated until 24 March 2021.

Description of the target populations

Document review

The target population included patients discharged from the hospital
after admission for COVID-19–related illness.

The draft recommendation was reviewed by all members of the
panel and made available online from 8 to 19 July 2021 for external
review by stakeholders, including allied organizations, other medical
professionals, patients, and the public. As part of the public comment, there were 143 views; 2 individuals or organizations submitted responses that did not require changes to the document. On
10 August 2021, the ASH Guideline Oversight Subcommittee and
the ASH Committee on Quality assured that the deﬁned guideline

Methods
This new guideline recommendation on the use of prophylacticintensity anticoagulation for patients being discharged after admission for COVID-19–related illness was developed in the living phase
of the ASH 2021 Living Guidelines on the Use of Anticoagulation
666
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Evidence review and development of
recommendations
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Thrombosis has emerged as an important complication of patients
hospitalized with COVID-19–related acute or critical illness, with
VTE occurring in up to 8% and 23% of such patients, respectively.4
This result aligns with the recognition that patients hospitalized for
other acute medical illnesses, such as pneumonia, stroke, and heart
failure, are at increased risk of VTE. Predictors of VTE in such medically ill inpatients include reduced mobility, advanced age, active
cancer, and prior VTE.23,24 Previously published ASH guidelines
provided focused recommendations for the prevention of VTE in
hospitalized patients with COVID-19, and in non-COVID-19 medical
inpatients.7,25,26

for Thromboprophylaxis for Patients with COVID-19. The ASH
guideline panel added this question as a priority in January 2021
and generated recommendation 3 on 14 April 2021 before asking
for public comments.

Table 1. Recommendations
Recommendation

Remarks

Recommendation 3. The ASH guideline panel suggests that outpatient anticoagulant
thromboprophylaxis not be used in patients with COVID-19 who are being
discharged from the hospital and who do not have suspected or conﬁrmed VTE or
another indication for anticoagulation (conditional recommendation based on low
).
certainty in the evidence about effects 丣

How to use these guidelines
We refer readers to the description in the initial guideline publication
of February 2021,7 as well as the user guide to ASH clinical practice guidelines.37

Recommendations
Patients being discharged from the hospital after
admission for COVID-19
Should prophylactic-intensity direct oral anticoagulants, low-molecular-weight heparin, unfractionated heparin, or fondaparinux vs no
anticoagulation be used for postdischarge thromboprophylaxis for
patients with COVID-19 who are discharged from the hospital and
who do not have suspected or conﬁrmed VTE or another indication
for anticoagulation?

Recommendation 3
The ASH guideline panel suggests that outpatient anticoagulant thromboprophylaxis not be used for patients with
COVID-19 who are discharged from the hospital and do
not have suspected or conﬁrmed VTE or another indication
for anticoagulation (conditional recommendation based on
very low certainty in the evidence about effects 丣
).
Remarks:




An individualized assessment of the patient’s risk of thrombosis
and bleeding and shared decision making are important when
deciding on whether to use postdischarge thromboprophylaxis.
Prospectively validated risk assessment models to estimate
thrombotic and bleeding risk of patients with COVID-19 after
hospital discharge are not available.
The panel acknowledged that postdischarge thromboprophylaxis
may be reasonable for patients judged to be at high risk of
thrombosis and low risk of bleeding.

Summary of the evidence. We rated the certainty in the evidence
as low for the outcome of major bleeding in patients without COVID19, owing to very serious indirectness, and as very low for all other outcomes, mainly owing to (very) serious risk of bias (see evidence proﬁle
and evidence to decision [EtD] framework online at https://guidelines.
ash.gradepro.org/proﬁle/uEXUjtWgVAQ). We found no systematic
25 JANUARY 2022 • VOLUME 6, NUMBER 2

reviews that addressed this question. Three observational studies provided evidence related to the question. Supplement 10 presents the
characteristics of the included studies.
One prospective registry study reported the effect of postdischarge
prophylactic-intensity anticoagulation on the outcomes of any VTE
or ATE, mortality, and bleeding5; 1 retrospective cohort study on the
outcome of any VTE or ATE38; and 1 matched case-control study
on the outcome of readmission.39
Benefits. The evidence was very uncertain for all of the considered
outcomes leading to the following interpretation. Postdischarge
prophylactic-intensity anticoagulation may reduce the risk of mortality
(odds ratio [OR] 0.55; 95% conﬁdence interval [CI], 0.37-0.83),
which corresponds to 5 fewer (from 7 fewer to 2 fewer) deaths per
1000 patients; very low certainty. Postdischarge prophylacticintensity anticoagulation may reduce the risk of PE (OR, 0.76; 95%
CI, 0.46-1.25), which corresponds to 1 fewer (from 3 fewer to 1
more) PEs per 1000 patients; very low certainty. Postdischarge
prophylactic-intensity anticoagulation may reduce the risk of VTE
(OR, 0.76; 95% CI, 0.46-1.25), which corresponds to 4 fewer
(from 9 fewer to 4 more) VTEs per 1000 patients; very low certainty. Postdischarge prophylactic-intensity anticoagulation may
reduce the risk of readmission (OR, 0.92; 95% CI, 0.41-2.05),
which corresponds to 5 fewer (from 35 fewer to 57 more) readmissions per 1000 patients; very low certainty. No beneﬁt or harm was
observed for the outcomes of DVT, ischemic stroke, and
ST-elevation myocardial infarction in terms of absolute effect, but
there was very low certainty in the evidence.
Harms and burden. Indirect evidence from acutely ill patients
who do not have COVID-19 indicated that postdischarge
prophylactic-intensity anticoagulation after hospitalization may
increase the risk of major bleeding (relative risk, 2.09; 95% CI,
1.33-3.27), but the evidence is uncertain; this corresponds to 4
more (from 1 more to 9 more) major bleeding episodes per 1000
patients at lower risk of bleeding, and to 13 more (from 4 more to
27 more) major bleeding episodes per 1000 patients at higher risk
of bleeding; low certainty. Direct evidence from patients acutely ill
with COVID-19 indicates that postdischarge prophylactic-intensity
anticoagulation may increase the risk of major bleeding but the evidence is very uncertain (OR, 1.52; 95% CI, 0.86-2.67). This result
corresponds to 1 more (from 0 to 2 more) major bleeding episode
per 1000 patients; very low certainty.
Other EtD criteria and considerations. The guideline panel
noted that there was possible uncertainty and variability in the relative value patients place on reducing thrombotic events compared
with avoiding major bleeding events. The panel agreed that the use
ASH GUIDELINES ON ANTICOAGULATION IN COVID-19 667
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development process was followed, and on 12 August 2021, the
ofﬁcers of the ASH Executive Committee approved submission of
the updated guideline manuscript for publication under the imprimatur of ASH. The updated guideline was then subjected to peer
review by Blood Advances.

An individualized assessment of the patient’s risk of thrombosis and bleeding and
shared decision making are important when deciding whether to use postdischarge
thromboprophylaxis. Prospectively validated risk assessment models to estimate
thrombotic and bleeding risk in patients with COVID-19 after hospital discharge are
not available.
The panel acknowledged that postdischarge thromboprophylaxis may be reasonable in
patients judged to be at high risk of thrombosis and low risk of bleeding.

suggests that postdischarge thromboprophylaxis be considered for
all patients hospitalized with COVID-19 who meet high-risk VTE criteria, including advanced age, ICU admission, cancer, prior VTE history, thrombophilia, severe immobility, elevated D-dimer, or an
IMPROVE VTE score of 4 or more.42 The guidance from AC Forum,
NIH, and ACC all suggest that postdischarge prophylaxis be considered in light of thrombotic risk, bleeding risk, and access to
medication.

Conclusions for this recommendation. The panel judged
both the beneﬁts and harms of postdischarge thromboprophylaxis
to be trivial in terms of absolute effects. Although there was a trivial
mortality beneﬁt and reduction in VTE with postdischarge anticoagulant therapy, there was very low certainty in the evidence.

At the time of this writing, there have been no published randomized
trials examining the efﬁcacy and safety of postdischarge thromboprophylaxis in patients with COVID-19. However, there are several
ongoing or recently completed clinical studies examining this question.47 These prospective studies include the MICHELLE (registered
at https://clinicaltrial.gov, as NCT04662684)48 and ACTIV-4c trials
(NCT04650087),49 which examine the use of prophylactic-intensity
direct oral anticoagulants.

Meanwhile, there was less uncertainty in the potential undesirable
effects of anticoagulant therapy in increasing the risk of major bleeding complications. Although there was no direct high-quality evidence available for patients with COVID-19, the panel considered
that there was higher quality indirect evidence for patients without
COVID-19 that indicated an increase in the risk of major bleeding
when postdischarge anticoagulation was used.32,40,41
The panel judged that the major bleeding complications outweigh
the potential beneﬁts (particularly given the relatively low baseline
risk of postdischarge VTE) and that, overall, the undesirable consequences outweigh the desirable consequences. On the basis of
these judgments, the panel suggests that postdischarge thromboprophylaxis not be used.26 However, the panel emphasized the
importance of an individualized decision for each patient based on
an assessment of thrombosis and bleeding risks.

What are others saying and what is new in
these guidelines?
There are multiple other guidance documents on the use of anticoagulation in patients with COVID-19. These include the 2020
CHEST COVID-19 Guidelines, Anticoagulation Forum interim clinical guidance, International Society on Thrombosis and Haemostasis
(ISTH) Scientiﬁc and Standardization Committee (SSC) COVID-19
clinical guidance, National Institutes of Health (NIH) COVID-19
treatment guidelines, and American College of Cardiology (ACC)
clinical guidance.42-46
Major differences between the current ASH guidelines and these
other documents include use in ASH guidelines of high-quality systematic reviews and ED frameworks, which increase transparency,
along with the use of marker states to estimate the relative importance to patients of key outcomes of treatment. The present ASH
guideline is also unique in its “living” format, though other guidance
documents may also be updated.
All 5 of these other guidance documents do not recommend routine
use of postdischarge pharmacological thromboprophylaxis after hospitalization for COVID-19–related illness. However, given the lack of
high-quality evidence, they all suggest that an individualized decision
be made taking into account the patient’s thrombosis risk factors
and bleeding risk at the time of discharge.
The CHEST guideline suggests that postdischarge thromboprophylaxis would result in net clinical beneﬁt only if the risk of symptomatic
VTE were found to be .1.8% within 35 to 42 days after release
from the hospital.44 Meanwhile, the ISTH guidance document
668
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Limitations of these guidelines
The limitations of these guidelines are inherent in the low certainty in
the evidence we identiﬁed for the research questions. In addition,
the use of treatments other than anticoagulants for management of
COVID-19–related acute and critical illness (eg, corticosteroids,
anticytokine therapies, ventilatory support), the affected patient population, as well as the emergence of different viral variants has
changed over the course of the pandemic. These changes may
affect the baseline risk of VTE. Evidence collected earlier in the pandemic and included in our systematic reviews may not fully reﬂect
the baseline risk of VTE or the effect of postdischarge thromboprophylaxis in the current phase of the pandemic.

Plans for updating these guidelines
These recommendations will be updated based on a living review of
evolving evidence, including data from randomized trials. See the initial guideline publication for methods of living systematic reviews
and recommendations, including considerations for deciding when
to reassess and update recommendations.7

Updating or adapting
recommendations locally
Adaptation of these guidelines will be necessary in many circumstances. These adaptations should be based on the associated EtD
frameworks.15

Priorities for research
On the basis of gaps in evidence identiﬁed during the guideline
development process, the panel identiﬁed the following urgent
research priorities in this patient population:






Studies assessing baseline VTE risk after hospitalization in
patients with COVID-19–related illness.
Randomized controlled trials comparing antithrombotic therapy
(including anticoagulants and antiplatelet agents) for thromboprophylaxis after hospitalization.
Identiﬁcation of predictors of thrombosis and bleeding in patients
discharged after COVID-19–related illness.
Development and validation of risk assessment models for
thrombosis and bleeding risk in patients discharged after
COVID-19–related illness.
25 JANUARY 2022 • VOLUME 6, NUMBER 2
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of postdischarge anticoagulant thromboprophylaxis would be
acceptable to patients and health care providers. In addition, the
panel acknowledged that patients who are not insured may have
reduced access to postdischarge anticoagulant therapy, which
could adversely affect health care equity. There would be a potential
for increased costs for those paying out of pocket for postdischarge
prophylaxis.





Studies examining the impact of nonanticoagulant interventions
(eg, anticomplement therapy, corticosteroids, antiviral therapies,
anticytokine therapies, antiplatelet therapies, monoclonal antibody therapy, convalescent plasma) on risk of thrombosis after
hospital discharge.
Studies examining the impact of anticoagulant therapy on thrombosis and bleeding outcomes after hospitalization in patients of
different racial and ethnic backgrounds.
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